Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)

Next Previous
Search
Trial Profile

Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Lapatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TYCO
  • Sponsors GlaxoSmithKline

Most Recent Events

  • 25 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 21 Apr 2015 Planned End Date changed from 1 Apr 2015 to 1 Aug 2015 as per ClinicalTrials.gov record.
  • 21 Apr 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Aug 2015 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top